Breast Cancer News

Skip to content
  • Home
  • What Is Breast Cancer?
    • Types of Breast Cancer
    • Breast Cancer Classification
    • Causes of Breast Cancer
      • Breast Tissue Density
      • Risk Factors
    • Signs and Symptoms
      • Breast Lump or Mass
      • Breast or Nipple Pain
      • Breast Swelling & Inflammatory Breast Cancer
      • Nipple or Breast Skin Alterations
      • Nipple Retraction
      • Skin Irritation or Dimpling
    • Diagnosis of Breast Cancer
    • Stages
    • Breast Cancer Statistics
    • Breast Cancer During Pregnancy
  • Treatment
    • Bone-directed Therapy
    • Chemotherapy
    • Surgery
      • Mastectomy
      • Breast Reconstruction
    • Radiation Therapy
    • Targeted Therapy
    • Ado-Trastuzumab Emtansine (Kadcyla)
    • Albumin-Bound Paclitaxel (Nab-Paclitaxel or Abraxane)
    • Anastrozole (Arimidex)
    • Capecitabine (Xeloda)
    • Cyclophosphamide (Clafen, Cytoxan, and Neosar)
    • Docetaxel (Taxotere)
    • Epirubicin Hydrochloride (Ellence)
    • Eribulin (Halaven)
    • Everolimus (Afinitor)
    • Exemestane (Aromasin)
    • Gemcitabine Hydrochloride (Gemzar)
    • Goserelin Acetate (Zoladex)
    • Ixabepilone (Ixempra)
    • Lapatinib Ditosylate (Tykerb)
    • Letrozole (Femara)
    • Lynparza (Olaparib)
    • Nerlynx (Neratinib)
    • Tecentriq
    • Experimental Treatments
      • GBR 1302
      • GMI-1359
  • Columns
    • A Lump in the Road
    • Journeying Toward the Pink Path
    • Protecting the Pecs
    • Chemo and Cocktails: A Young Survivor’s Guide
  • COVID-19 Info
    • COVID-19 Updates

Diabetes Medication Used in Asia Seen to Target Aggressive Basal-like Breast Cancer

March 15, 2017March 15, 2017
Alice Melãoby Alice Melão

In News.

Diabetes Medication Used in Asia Seen to Target Aggressive Basal-like Breast Cancer

Click here to subscribe to the Breast Cancer News Newsletter!

An enzyme known as AKR1B1 is highly expressed in basal-like breast cancer (BLBC) cells and appears to be an important mediator of cancer aggressiveness and metastatic ability, researchers in China reported. But their work also showed that a diabetes drug —  epalrestat, approved in a few countries to treat diabetes-associated peripheral neuropathies by inhibiting AKR1B1 — is a potential therapy for BLBC patients.

The study, “AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program,” was published in The Journal of Experimental Medicine.

BLBC is an aggressive breast cancer subtype found in about 15 percent to 20 percent of patients. Characterized by its ability to spread, or metastasize, very quickly and to induce early recurrence after treatment, it frequently progresses to the lungs and brain. This form of breast cancer still lacks an efficient targeted therapy, and many BLBC patients have a poor prognosis.

BLBC cells activate a specific cellular process called epithelial-mesenchymal transition (EMT), in which cancer cells acquire the characteristics needed for cancer progression and metastasis.

Working with about 800 samples from breast cancer patients, the researchers found that the gene coding for AKR1B1 enzyme was highly expressed in BLBC samples compared to other cancer subtypes.

They found that this increased expression was regulated by another protein, called Twist2, known for its role in activating EMT. The AKR1B1 enzyme was shown to be an important regulator of this process, being necessary for BLBC cells to acquire stem cell-like properties to migrate and invade other organs.

Further experiments with breast cancer animal models confirmed these observations; lowering the levels of AKR1B1 slowed the growth and progression of BLBC tumors.

“Our data clearly suggests that AKR1B1 overexpression represents an oncogenic event that is responsible for the aggressive behaviors of basal-like breast cancer cells,” the study’s senior author, Chenfang Dong, said in a news release.

The authors also tested the efficacy of epalrestat, an aldose reductase inhibitor that blocks AKR1B1 and is approved in Japan (under the brand name, Kinedak) and China (possibly in generic form) to treat diabetes-associated complications. Epalrestat was able to efficiently block the pro-tumor effects of AKR1B1 in breast cancer animal models.

“Since epalrestat is already on the market and has no major adverse side effects, our study provides a proof of principle that it could become a valuable targeted drug for the clinical treatment of basal-like breast cancer,” Dong said.

Print This Page

Tagged AKR1B1, Basal-like breast cancer (BLBC), Epalrestat, Epithelial-mesenchymal transition (EMT), Kinedak, Twist2.

Post navigation

Previous: What a Nighttime Routine Looks Like When You Have a Chronic Illness
fda-approved treatmentNext:FDA Approves CDK4/6 Inhibitor, Kisqali, to Treat Type of Metastatic Breast Cancer

Recent Posts

  • Enhertu conditional approval U.K.

    Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

    February 22, 2021

  • IRX-2 Phase 2 trial

    Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

    February 18, 2021

  • Tukysa, EU approval

    Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

    February 15, 2021

Featured Post

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

June 30, 2020

Visit Breast Cancer News's profile on Pinterest.

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

July 1, 2020

Phesgo approved

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

May 7, 2020

FDA approval

Bionews, Inc.
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • Publishing Team
  • Leadership
  • Our Values
  • Terms of Service
  • Privacy Policy
  • Corrections Policy
  • Contact Us

Disclaimer:

Breast Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2025 All rights reserved.